research Hand-Foot and Stump Syndrome to Sorafenib
Sorafenib may cause hand-foot and stump syndrome, requiring early detection and management.
Search
for
Sort by
Research
480-510 / 1000+ results
research High incidence of severe hand–foot syndrome during capecitabine–docetaxel combination chemotherapy
About half the patients treated with capecitabine and docetaxel developed severe hand-foot syndrome.
research Cutaneous toxicities of cancer therapy
Cancer therapy can cause various skin problems, including hair loss, skin darkening, painful hand-foot syndrome, and severe skin damage.
research Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer
PLD is an effective and safer alternative for treating breast cancer.
research Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer
Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
research Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.
research Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
BRAF inhibitors for melanoma often cause skin side effects, but they can be managed with proper care.
research Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs
New cancer drugs often cause skin and nail problems.
research Non-Rash Skin Toxicities Associated with Novel Targeted Therapies
Early recognition and management of skin side effects from new cancer therapies can prevent treatment delays.
research Skin toxicity of anti‐cancer therapy
Anti-cancer treatments can cause reversible hair loss, skin sensitivity, pigmentation changes, nail damage, and skin reactions, with a need for more research on managing these side effects.
research Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
Sorafenib after liver surgery may increase survival for some liver cancer patients.
research Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
research Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
Sorafenib often causes mucositis, hand-foot syndrome, rash, alopecia, diarrhea, and fatigue.
research The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis
Combined BRAF and MEK treatment increases rash risk but reduces other skin issues compared to BRAF alone.
research Targeted Therapy– and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis
Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.
research Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
Cancer treatments often cause skin, nail, and hair problems.
research Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management
Targeted anticancer therapies often cause skin issues, affecting treatment adherence and quality of life.
research Chemotherapy and the Skin: Understanding Dermatologic Side Effects
Recognizing and managing skin side effects from chemotherapy improves patient quality of life and treatment success.
research Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
Early intervention and tailored management are crucial for skin side effects in cancer treatments.
research Comparative Outcomes of Cutaneous Vesicostomy Versus Cystoscopic Valve Ablation in the Initial Management of Posterior Urethral Valves
Cutaneous vesicostomy and cystoscopic valve ablation both have pros and cons for managing posterior urethral valves.
research [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
research Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses
Apremilast improved symptoms in patients with severe skin conditions.
research Gender-specific side effects of chemotherapy in pancreatic cancer patients
Women with pancreatic cancer are more likely to have certain side effects from chemotherapy than men.
research Sorafenib-induced Facial Acneiform Eruption
Low-dose sorafenib can cause severe facial acne, treatable with topical medication.
research Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
research Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib
Sorafenib often causes skin side effects, indicating effective cancer treatment.
research A New Application in Dermatological Ultrasound
The document concludes that the acoustic coupler SF-001 is good for skin ultrasound, especially on rough body parts, because it's stable and shows blood vessels well.
research WNT10B (wingless-type MMTV integration site family)
WNT10B is linked to cancer development and affects survival and disease progression in various cancers.
research Reporting on Adverse Clinical Events
Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.
research America - A Diversity of Life Styles.
The drug showed promise in treating renal cell carcinoma with manageable side effects.